SAN DIEGO, March 14 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today that it will release its financial results for the year ended December 31, 2007 on Thursday, March 20, 2008 after the close of the U.S. financial markets.
CryoCor will also hold a Web cast and conference call at 5:00 p.m. ET / 2:00 p.m. PT on March 20, 2008. Management will discuss the financial results, provide an update on the commercialization of the Company's Cardiac Cryoablation System for the treatment of right atrial flutter and discuss the Company's strategic objectives for 2008.
The dial-in numbers are 1-877-407-4018 for domestic callers and 1-201-689-8471 for international callers. A live Web cast of the conference call will be available online from the investor relations page of the Company's corporate Web site at http://www.cryocor.com.
After the live Web cast, the call will remain available on CryoCor's Web site for at least 30 days following presentation. In addition, a telephonic replay of the call will be available. The replay dial-in numbers are 1-877-660-6853 for domestic callers 1-201-612-7415 for international callers. Please use account number 3055 and conference ID number 278655.
CryoCor is a medical technology company that has developed and
manufactures a disposable catheter system based on its proprietary
cryoablation technology for the minimally invasive treatment of cardiac
arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation
System, or the Cryoablation System, is designed to treat cardiac
arrhythmias through the use of cryoenergy, or extreme cold, to destroy
targeted cardiac tissue. The Cryoablation System has been approved in
Europe for the treatment of atrial fibrillation, and atrial flutter, the
two most common and difficult to treat arrhythmias, since 2002. In the
United States, CryoCor is conducting a pivotal trial to evaluate the safety
and efficacy of the Cryoablation System for the treatment of atrial
fibrillation and the Cryoablation System has been approved for the
treatment of right atrial flutter. For more information please visit the
Company's website at http://www.cryocor.com.
CryoCor The Ruth Group
Gregory J. Tibbitts Nick Laudico / Zack Kubow (investors)
Chief Financial Officer (646) 536-7030 / 7020
(858) 909-2200 email@example.com
Jason Rando (media)
|SOURCE CryoCor, Inc.|
Copyright©2008 PR Newswire.
All rights reserved